Golden Biotechnology Corporation
Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and … Read more
Golden Biotechnology Corporation (4132) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.282x
Based on the latest financial reports, Golden Biotechnology Corporation (4132) has a cash flow conversion efficiency ratio of -0.282x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-67.83 Million) by net assets (NT$240.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Golden Biotechnology Corporation - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Golden Biotechnology Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Golden Biotechnology Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Golden Biotechnology Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CCK Consolidated Holdings Bhd
KLSE:7035
|
0.024x |
|
Greenland Minerals And Energy Ltd
PINK:GDLNF
|
-0.101x |
|
Scana ASA
OL:SCANA
|
0.064x |
|
Yuhwa Securities Co Ltd
KO:003465
|
0.183x |
|
Gateway Mining Ltd
AU:GML
|
-0.016x |
|
SNS
KLSE:0259
|
-0.411x |
|
G&E Herbal Biotechnology Co., Ltd.
TWO:4911
|
0.004x |
|
Amicogen Inc
KQ:092040
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Golden Biotechnology Corporation (2019–2023)
The table below shows the annual cash flow conversion efficiency of Golden Biotechnology Corporation from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$402.10 Million | NT$-271.32 Million | -0.675x | -109.82% |
| 2022-12-31 | NT$764.67 Million | NT$-245.90 Million | -0.322x | -68.27% |
| 2021-12-31 | NT$1.04 Billion | NT$-197.96 Million | -0.191x | +35.20% |
| 2020-12-31 | NT$880.27 Million | NT$-259.60 Million | -0.295x | +9.75% |
| 2019-12-31 | NT$682.39 Million | NT$-222.98 Million | -0.327x | -- |